

REMARKS

Support for newly added claims 27 through 30 may be found in the Specification at, for example, page 2, lines 21 – 24 and page 3, lines 4 – 16, and as such these amendments do not introduce new matter into the Specification under 37 CFR 1.121.


Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned **"Version with markings to show changes made."**

Conclusion

It is submitted that the foregoing amendments and remarks place the case in condition for allowance. A notice to that effect is earnestly solicited.

Respectfully submitted,

By: _____


Michele G. Mangini
(Attorney for Applicants)
Reg. No. 36,806

Dated: 7 October 2001

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2810

MCP264.amt

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

The following claims were added:

-- (New) 27. The method of claim 1 wherein the pharmaceutically acceptable salt of ibuprofen is

a) an inorganic cation salt selected from sodium, potassium, lithium, calcium, cesium, ammonia, ferrous, zinc, manganous, aluminum, ferric, and manganic;

b) an organic salt of ibuprofen with primary, secondary, tertiary and quaternary amines selected from triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine, caffeine, procain, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, TRIS(hydroxymethyl)aminomethane, methylglycamine, theobromine, prunes, piperazine, piperidine, and polyamine resins; or

c) mixtures thereof. --

-- (New) 28. The method of claim 4 wherein the pharmaceutically acceptable salt of ibuprofen is a) an inorganic cation salt selected from sodium, potassium, lithium,

calcium, cesium, ammonia, ferrous, zinc, manganous, aluminum, ferric, and manganic;

b) an organic salt of ibuprofen with primary, secondary, tertiary and quaternary amines selected from triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine, caffeine, procain, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, TRIS(hydroxymethyl)aminomethane, methylglycamine, theobromine, prunes, piperazine, piperidine, and polyamine resins; or

c) mixtures thereof. --

-- (New) 29. A method for mitigating or treating photophobia associated with migraine to a patient in need thereof comprising:

providing an effective amount of ibuprofen and or isomer thereof as the sole pharmaceutically effective ingredients. --

-- (New) 30. A method for mitigating or treating phonophobia associated with migraine to a patient in need thereof comprising:

providing an effective amount of ibuprofen and or isomer thereof as the sole pharmaceutically effective ingredients. --